Related Experiment Videos
An evaluation of netilmicin, 150 mg BID, in systemic infections
Abstract:
The efficacy and tolerance of netilmicin administered in a simplified dosage schedule (150 mg BID) were evaluated in an open study of 20 patients with acute systemic infections. Duration of therapy ranged from 6 to 11 days. All isolated causative organisms were eradicated; 85% (17/20) of the patients experienced complete clinical resolution, and the remaining 15% (3/20) experienced definite improvement. No patients developed nephrotoxicity of ototoxicity. The results of this study demonstrate that netilmicin is both effective in the treatment of serious systemic infections and well tolerated when administered at 150 mg twice daily.
Insights
Netilmicin at 150 mg twice daily effectively treated acute systemic infections in 20 patients. This antibiotic regimen showed high clinical resolution and no adverse effects like nephrotoxicity or ototoxicity.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Background:
- Acute systemic infections require effective and well-tolerated antibiotic treatments.
- Aminoglycosides, such as netilmicin, are crucial for managing severe bacterial infections.
- Optimizing dosage schedules can improve patient compliance and reduce toxicity risks.
Purpose of the Study:
- To evaluate the efficacy and safety of a simplified twice-daily (BID) dosage schedule of netilmicin.
- To assess the clinical outcomes and microbiological eradication in patients with acute systemic infections.
- To determine the incidence of nephrotoxicity and ototoxicity with this dosing regimen.
Main Methods:
- An open-label study was conducted involving 20 patients diagnosed with acute systemic infections.
- Patients received netilmicin at a dosage of 150 mg twice daily for 6 to 11 days.
- Clinical resolution, microbiological eradication, and adverse events (nephrotoxicity, ototoxicity) were monitored.
Main Results:
- All causative organisms were eradicated in the studied patient cohort.
- Complete clinical resolution was achieved in 85% (17/20) of patients.
- Definite clinical improvement was observed in the remaining 15% (3/20) of patients, with no instances of nephrotoxicity or ototoxicity.
Conclusions:
- Netilmicin administered at 150 mg BID is an effective treatment for acute systemic infections.
- The simplified twice-daily dosage schedule of netilmicin is well-tolerated, with a favorable safety profile.
- This regimen presents a viable therapeutic option for serious infections, minimizing the risk of kidney and hearing damage.